Abstract: Cyclodextrins (CDs) are cyclic oligosaccharides which can trap hydrophobic molecules and improve their chemical, physical, and biological properties. γ-CD showed the highest aqueous solubility with the largest cavity diameter among other CD types. The current study describes a direct and easy method for nucleophilic mono-aminos to be substituted with γ-CD and tested for their ability to host the guest curcumin (CUR) as a hydrophobic drug model. The mass spectrometry and NMR analyses showed the successful synthesis of three amino-modified γ-CDs: mono-6-amino-6-deoxy-cyclodextrine (γ-CD-NH₂), mono-6-deoxy-6-ethanolamine-γ-cyclodextrine (γ-CD-NHCH₂CH₂OH), and mono-6-deoxy-6-aminoethylamino-γ-cyclodextrin (γ-CD-NHCH₂CH₂NH₂). These three amino-modified γ-CDs were proven to be able to host CUR as native γ-CDs with formation constants equal to 6.70 ± 1.02, 5.85 ± 0.80, and 8.98 ± 0.90 M⁻¹, respectively. Moreover, these amino-modified γ-CDs showed no significant toxicity against human dermal fibroblast cells. In conclusion, the current work describes a mono-substitution of amino-modified γ-CDs that can still host guests and showed low toxicity in human dermal fibroblasts cells. Therefore, the amino-modified γ-CDs can be used as a carrier host and be conjugated with a wide range of molecules for different biomedical applications, especially for active loading methods.

Keywords: cyclodextrins; γ-CDs; host-guest complexes; curcumin; mono-amino substitution; weak base modification; drug carrier

1. Introduction

Cyclodextrins (CDs) are cyclic oligomers of glucose units, derived from the bacterial enzymatic reactions of starch, consisting of six, seven, and eight D-glucopyranose units linked by α-1,4-glycosidic linkages, called α-, β-, and γ-cyclodextrin, respectively [1,2]. CDs have truncated cone shapes of different sizes, with a hydrophobic cavity resulting from the methane and oxygen groups, and a hydrophilic exterior (upper and lower rim surface), due to the presence of primary and secondary hydroxyl groups. CDs are approved for use as food additives by the US Food and Drug Administration (FDA) and the World Health Organization–Food and Agriculture Organization of the United Nations (WHO–FAO) [3].

These compounds are widely used in the pharmaceutical field to improve the aqueous solubility, dissolution rate, chemical stability, and bioavailability of hydrophobic drugs [2]. In particular, the hydrophobic cavity of CDs enables them to encapsulate hydrophobic molecules of suitable sizes and generate inclusion complexes [4], which is called host–guest complexation [5]. This remarkable property of encapsulation of guest molecules is applied in many
fields, including medicine, materials science, food, and agricultural industries [6–9]. The natural β-CD is the most commonly used CD in industrial products. β-CD accounts for about 70% of the global CD production, while α-CD is about 15%, and γ-CD is about 5% [10].

Recently, CDs have been utilized in cancer treatment due to their ability to enhance the aqueous solubility of hydrophobic anti-cancer flavonoids, such as curcumin and quercetin [11–13]. Compared with free curcumin, β-CD-curcumin has an enhanced solubility with a greater cellular uptake and a longer half-life, along with higher anti-proliferative and anti-inflammatory activities against leukemic, pancreatic, and tubulin surface cancer cells [11,12]. Yadav et al. reported that the CUR-β-CD complexation enhanced CUR solubility, and increased the CUR potency and the cellular uptake that induced apoptosis in tumor cells [11]. Moreover, the inclusion complex of the novel curcumin analogue CDF and β-cyclodextrin (1:2) enhanced the in vivo anti-cancer activity against pancreatic cancer [12]. Furthermore, Zhang et al. investigated the use of CUR-cyclodextrin complexes (CD15) as an approach to cancer chemoprevention. CD15 enhanced CUR delivery and improved its therapeutic efficacy compared to free CUR, both in vivo and in vitro [13]. Similarly, the aqueous solubility of quercetin improved linearly with increasing concentrations of three different β-CD derivatives: hydroxypropyl-β-CD, sulfobutyl ether-β-CD, and methylated-β-CD [14].

The primary hydroxyl groups on the CDs’ exterior are the less hindered and more nucleophilic, which can be easily derivatized; therefore, a large variety of charged or uncharged derivatives is available [15,16]. Such modifications offer the possibility of enhancing the CDs’ physiochemical characteristics and opening the door for more pharmaceutical applications. These new CDs derivatives not only retain the binding ability of guest hydrophobic small and large molecules into the hydrophobic cavity, but also introduce new interactions with substituents at the rims, which are relatively well-hydrated [17]. Currently, the most commonly applied cyclodextrin derivatives are randomly methylated β-CD, 2-hydroxypropylated-β-CD, sulfobutylether-β-CD, sulfated-β-CD, and carboxymethyl-β-CD [6,17]. Commercially available modified CDs are generally limited to β-CD and to a multi- or random substitution of γ-CD [6]. Random substitution of CDs is not desirable for the hosts when binding selectivity is desired. Moreover, the resulting derivatives should be water-soluble and should not aggregate in the solution, so that accurate host–guest binding measurements can be carried out. γ-CD has the highest water solubility among other CDs, with a solubility of 23.2 g/mL, compared to 1.85 and 14.5 g/100 for γ-CD, β-CD, and α-CD, respectively [5]. Moreover, γ-CD has a larger hydrophobic cavity compared to other types of CDs, capable of accommodating large structure phytochemicals with potential anti-cancer effects [3]. γ-CD is considered safe due to its lower toxicity, and is the only native CD that undergoes complete digestion in the gastrointestinal tract [10]. However, the only commercially available derivatives for γ-CD are multi- and randomly substituted ones [18]. Accordingly, this work aims to provide a simple and easy synthesis protocol for water-soluble γ-CD derivatives that are singly substituted and still able to host a guest molecule (Scheme 1). Providing such a weak base and/or nucleophilic mono-amino substituted for γ-CD enables extra bioconjugation for a wide variety of small and large molecules, or even certain carboxylated polymers [19]. In addition, this weak base modification of CDs enhances the encapsulation efficiency of hydrophobic drugs in the liposomes aqueous core [15,20].
2. Results and Discussion

2.1. Characterization of Modified γ-CDs

2.1.1. NMR and HR Mass Spectrometry

The formation of the three modified γ-CDs (γ-CD-NHCH₂CH₂OH, γ-CD-NHCH₂CH₂NH₂, and γ-CD-NH₂) was investigated using NMR and HR mass spectrometry. The HRMS (ESI) positive mode ([M + H]⁺) showed calculated and found mass values for γ-CD-NHCH₂CH₂OH (C₅₀H₈₆N₀₄₀) of 1340 and 1335.40, respectively (Figure 1a). The mono-substituted γ-CD-NHCH₂CH₂NH₂ formation (C₅₀H₈₆N₂O₃₉) was also confirmed by the HRMS (ESI) positive mode ([M + H]⁺) with calculated mass values of 671.1565 and 671.255, respectively (Figure 1b). Furthermore, the mono substitution for the formation of γ-CD-NH₂ (C₄₈H₈₁N₀₃₉) was also confirmed with calculated mass values on the positive mode ([M + H]⁺) of 1295.4332 and 1295.4343, respectively (Figure 1c) [21].

The formation of the three modified γ-CDs (γ-CD-NHCH₂CH₂OH, γ-CD-NHCH₂CH₂NH₂, and γ-CD-NH₂) was also confirmed using NMR spectroscopy (all spectra are in the Supplementary Information). The appearance of several new signals (compared with NMR data for γ-CD (Figure S1)) confirms the formation of these derivatives. For γ-CD-NHCH₂CH₂NH₂, the appearance of new signals at 2.4 ppm corresponds to the –CH₂CH₂- of the ethylene diamine group and have an integration ratio of ~4 to 7, relative to the C1H signal at 4.9 ppm (Figure 2a). In addition, several signals correspond to the NH, NH₂, and C1–C6 protons of the glucose unit that underwent substitution. The ¹³C-dept ¹³C NMR spectrum for this compound is shown in Figure 2b. The most important signal is the CH₂ signal at 43 ppm which appeared due to substitution. The assignment was further confirmed using ¹H-¹⁵N-HMBC (Figure S2), showing the presence of two ¹⁵N environments. The mono-substituted γ-CD-NHCH₂CH₂OH was also confirmed using ¹H-NMR and ¹³C-NMR (Figures S5 and S6). The appearance of two new signals at 2.1 ppm and 3.6 ppm indicates the formation of the derivative and the supporting elements.
mass spectrum (Figure 1a). In the $^{13}$C-NMR spectrum, two new signals appeared at 39.4 ppm and 31.1 ppm (Figure S6) for two CH$_2$ carbon atoms.

2.1.2. Thermo-Gravimetric Analysis (TGA)

The thermal profiles of γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NHCH$_2$CH$_2$OH, and γ-CD-NH$_2$ are shown in Figure 3, with the temperature ranging between 30 °C and 400 °C. The thermal change occurred between 30 °C and 100 °C in different γ-CDs, due to the endothermic behavior which corresponded to the loss of water molecules in γ-CD’s surrounding and cavities. γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NHCH$_2$CH$_2$OH, and γ-CD-NH$_2$ start to decompose at 313.00, 286.80, 302.00, and 306.00 °C, respectively. The chemical modification of γ-CD decreases the decomposition temperature of γ-CD [22].

Moreover, the TGA thermogram showed a complete degradation, with almost 80% weight loss for the native γ-CD, compared to a better stability of the modified γ-CD-NHCH$_2$CH$_2$NH$_2$ and γ-CD-NHCH$_2$CH$_2$OH with around 75% weight loss. Meanwhile, γ-CD-NH$_2$ showed a relatively low stability compared to other CDs, with 94.2% weight loss. The % of the residual mass at 400 °C was 23% for the native γ-CD, and 25%, 27%, and 15% for γ-CD-NHCH$_2$CH$_2$OH, γ-CD-NHCH$_2$CH$_2$NH$_2$, and γ-CD-NH$_2$, respectively.

Figure 1. Mass spectra of (a) γ-CD-NHCH$_2$CH$_2$OH, (b) γ-CD-NHCH$_2$CH$_2$NH$_2$, and (c) γ-CD-NH$_2$ on the positive mode.
2.1.2. Thermo-Gravimetric Analysis (TGA)

The thermal profiles of γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NHCH$_2$CH$_2$OH, and γ-CD-NH$_2$ are shown in Figure 3, with the temperature ranging between 30 °C and 400 °C. The thermal change occurred between 30 °C and 100 °C in different γ-CDs, due to the

**Figure 2.** (a) $^1$H-NMR spectrum, (b) $^{13}$C-dept 135-NMR spectrum, and (c) $^1$H-$^{13}$C-HMQC-NMR for γ-CD-NHCH$_2$CH$_2$NH$_2$ in 80% $d_6$-DMSO and 20% D$_2$O at 25 °C.
Moreover, these variations also indicate different forms of the modified γ-CD-NH2. 

Figure 3. TGA thermograms of γ-CD-NHCH2CH2OH, γ-CD, γ-CD-NH2, and γ-CD-NHCH2CH2NH2.

2.2. Guest–Host Interaction between CUR and Modified γ-CDs by Absorption Spectra

The parent γ-CDs have no absorption in the range 300-500 nm, while CUR has a maximum absorption (λ_max) at 420 nm; hence, the wavelength 420 nm was used to investigate the complex formation between modified γ-CDs and CUR. The effect of the increasing concentration of γ-CD, γ-CD-NHCH2CH2NH2, γ-CD-NHCH2CH2OH, and γ-CD-NH2 on the absorption spectrum of CUR was studied with a constant concentration of CUR. As a result of complexation, the chromophore, CUR, was transferred from the aqueous environment into the hydrophobic environment of the cyclodextrin cavity, causing a hypochromic or bathochromic shift, which are the commonly reported effects of the complex formation [23]. Figure 4 shows an increase in the CUR absorbance upon the addition of γ-CD. This may be attributed to the enhanced aqueous solubility of CUR upon transference of one or two aromatic rings (chromophores) of CUR from the aqueous medium to the non-polar cavity of γ-CD [23]. γ-CD showed a hyperchromic shift compared to the pure CUR, while the modified γ-CD showed a hypochromic shift compared to the pure CUR and the native γ-CD, with decreasing absorption values from γ-CD-NHCH2CH2NH2 to γ-CD-NH2 and γ-CD-NHCH2CH2OH. The variations in the absorption values may be attributed to the different complexation patterns between the three different types of the modified γ-CD-NH2. Moreover, these variations also indicate different forms of the modified γ-CD-NH2.
2.3. Determination of the Complexation Stoichiometry and Formation Constants

The continuous variation method (Job’s method) was employed to determine the complexation stoichiometry, as shown in Figure 5, where the CUR mole fraction (X) varied from 0.0 to 1.0 and was plotted against the absorbance difference (ΔAbs) multiplied by the concentration of CUR. Job’s plot for the three different complexes showed a maximum peak at X = 0.5, which points to a 1:1 inclusion complex between CUR and different types of modified γ-CDs.

The binding constant (Kf) values for the 1:1 stoichiometric ratio between modified γ-CDs and the CUR inclusion complex were determined using the Benesi–Hildebrand equation (Equation (1)), after plotting 1/ΔA versus 1/[modified γ-CDs] (Figure 6). For a 1:1 stoichiometry, the formation constant (Kf) is equal to 8.98 ± 0.90 mM$^{-1}$ for γ-CD-

![Figure 4](image-url) Absorption spectra of (0.04 mM) CUR, (0.34 mM), CUR-γ-CD-NHCH₂CH₂OH, and CUR-γ-CD-NHCH₂CH₂NH₂. The same result was observed with γ-CD-NHCH₂CH₂OH, which has the smallest Kf value (5.85 mM$^{-1}$).

![Figure 5](image-url) Job’s plots for (a) CUR-γCD-NH₂, (b) CUR-γCD-NHCH₂CH₂NH₂, and (c) CUR-γCD-NHCH₂CH₂OH, where X is the mole fraction of CUR.

The binding constant (Kf) values for the 1:1 stoichiometric ratio between modified γ-CDs and the CUR inclusion complex were determined using the Benesi–Hildebrand equation (Equation (1)), after plotting 1/ΔA versus 1/[modified γ-CDs] (Figure 6). For a 1:1 stoichiometry, the formation constant (Kf) is equal to 8.98 ± 0.90 mM$^{-1}$ for γ-CD-
NHCH$_2$CH$_2$NH$_2$, 5.85 ± 0.80 mM$^{-1}$ for γ-CD-NHCH$_2$CH$_2$OH, and 6.70 ± 1.02 mM$^{-1}$ for γ-CD-NH$_2$.

2.4. Cytotoxicity Assay

The cytotoxic effect of γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NH$_2$, and γ-CD-NHCH$_2$CH$_2$OH was investigated against a normal human dermal fibroblast cell line (HDF) using an MTT assay. HDF cells were treated with different concentrations of γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NH$_2$, and γ-CD-NHCH$_2$CH$_2$OH for 72 h. The results revealed that no significant toxicity of γ-CD, γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NH$_2$, and γ-CD-NHCH$_2$CH$_2$OH was observed against HDF normal cells (Figure 7). These results confirmed the low toxicity of γ-CD-NHCH$_2$CH$_2$NH$_2$, γ-CD-NH$_2$, and γ-CD-NHCH$_2$CH$_2$OH and support the safe intended use as a drug carrier.

In conclusion, we have discussed the preparation and characterization of three amino-modified γ-CDs: mono-6-amino-6-deoxy-cyclodextrine (γ-CD-NH$_2$); mono-6-deoxy-6-ethanolamine-γ-cyclodextrine (γ-CD-NHCH$_2$CH$_2$OH); and mono-6-deoxy-6-aminoethylamino-γ-cyclodextrin (γ-CD-NHCH$_2$CH$_2$NH$_2$). NMR and HR mass data confirmed that modified γ-CDs were successfully prepared. These modified γ-CDs also showed low toxicity against normal human dermal fibroblast cell lines (HDF), making them suitable as drug carriers. In addition, CUR (which is considered an extremely hydrophobic natural compound) was successfully encapsulated in these modified γ-CDs, proving that these modifications did not affect γ-CD’s ability to form guest-host complexes. The stoichiometry of the inclusion complexes was determined using Job’s plot and the Benesi–Hildebrand equation.

Figure 6. Benesi–Hildebrand plot of 1/ΔA versus 1/[modified of γ-CDs] for CUR modified of γ-CDs inclusion complexes (a) γ-CD-NH$_2$, (b) γ-CD-NHCH$_2$CH$_2$NH$_2$, and (c) γ-CD-NHCH$_2$CH$_2$OH.
Figure 7. The dose–response curves of (a) γ-CD, (b) γ-CD-NH₂, (c) γ-CD-NH₂CH₂OH, and (d) γ-CD-NH₂CH₂NH₂ against HDF cells.

3. Materials and Methods

3.1. Chemicals

γ-cyclodextrin (γ-CD), curcumin, bis(4-hydroxy-3-methoxyphenyl)-1,6-diene-3,5-dione (CUR), and p-toluenesulfonyl chloride (TsCl) were purchased from Sigma (St. Louis, MO, USA). Sodium azide, 1,1,2,2-tetrachloroethane, pyridine, N,N-dimethylformamide (DMF), phosphate buffer saline (PBS), 1-ethanol-2-amine ethanolamine, and ethylenediamine were purchased from TEDIA (Fairfield, OH, USA). Deuterated dimethylsulfoxide (d₆-DMSO) (99.9% atom) was used for NMR analysis and was purchased from Aldrich (USA). Acetone, methanol, ethanol, acetonitrile, and 1-propanol were obtained from the Carbon Group (Carbon Group, Derbyshire, UK). All chemicals and solvents were of an analytical grade. All reagents and chemicals were used without further treatment.

3.2. Synthesis of Mono Amino Modified γ-CDs

The amino-modified γ-CDs, mono-6-amino-6-deoxy-cyclodextrine (γ-CD-NH₂), mono-6-deoxy-6-ethanolamine-γ-cyclodextrine (γ-CD-NH₂CH₂OH), and mono-6-deoxy-6-aminoethylamino-γ-cyclodextrin (γ-CD-NH₂CH₂NH₂), were synthesized as illustrated in Scheme 1. Firstly, mono-6-(p-toluenesulfonyl)-6-deoxy-γ-cyclodextrin (6-OTs-γ-CD) was synthesized by tosylation of γ-CD with p-toluenesulfonyl chloride (TsCl) in freshly dried pyridine, according to the literature procedure [21], with some modifications. Adapting the procedure described in the literature using a Schlenk line, 5.00 g (3.86 mmol) of γ-CD with 0.70 g (3.67 mmol) of TsCl yielded 6-Ots-γ-CD as a white solid (1.40 g, 25% yield).
Pure 6-Ots-γ-CD was obtained after its recrystallization in methanol: water (1:1). The amino-modified γ-CD-NHCH₂CH₂NH₂ and γ-CD-NHCH₂CH₂OH were synthesized by the nucleophilic substitution of 6-Ots-γ-CD according to the published procedure [22], using 6-Ots-γ-CD (0.24 mmol, 0.34 g) with an excess of aliphatic amine 1-ethanol-2-amine (17.63 mmol, 1.06 mL), forming a white precipitate. Suction filtration followed by recrystallization in methanol: water (1:1) yielded (51%, 0.160 g). Mono-6-azido-6-deoxy-cyclodextrin (γ-CD-N₃) was prepared according to Tang et al. [21] with some modification. The reduction of mono-6-azido-6-deoxy-cyclodextrin (γ-CD-N₃) was performed as illustrated in Scheme 1, where 1.00 g (0.79 mmol) of 6-Ots-γCD was added to 1.00 g (15.78 mmol) of sodium azide. A white solid γ-CD-N₃ was produced (0.5 g, 54%). Recrystallization was performed in hot methanol. The white solid γ-CD-N₃ was dried under a vacuum overnight at 60 °C. Mono-6-amino-6-deoxy-cyclodextrin (γ-CD-NH₂) was synthesized by mixing 0.20 g (0.16 mmol) of γ-CD-N₃, 0.046 g (0.18 mmol) of triphenylphosphine, and 0.32 mL DMF in a 50 mL one-neck round-bottomed flask. The product was precipitated using 3.3 mL of acetone, and then it was collected, washed again with acetone, and dried overnight to yield 0.161 g (77%).

3.3. Nuclear Magnetic Spectroscopy (NMR)

All NMR spectra were obtained in deuterated solvents (d₆-DMSO, D₂O, and CD₃OH (99.9% atom, Across Organics, Pittsburgh, PA, USA) using a Bruker Biospin AG Magnet system 500MHz/54mm instrument (Bruker Biospin, Fallanden, Switzerland) with a PA BBO 500S1 BBF-H-D-05 Z SP probe (Bruker Biospin, Fallanden, Switzerland), and the temperature was controlled using a variable temperature unit (VTU) and was held constant at 300 °K. Chemical shifts were measured in parts per million (ppm) and referenced to tetramethylsilane (TMS). The FID data were processed and analyzed using topspin Bruker software (Bruker Biospin GmbH, Billerica, MA, USA, version 4.1.3).

3.4. Mass Spectrometry

Positive or negative modes of high-resolution mass spectra (HR-MS) used the electrospray ion trap (ESI) technique by collision-induced dissociation on a Bruker APEX-4 (7 Tesla) instrument. The samples were infused using a syringe pump at a flow rate of 2 µL/min.

3.5. Thermo-Gravimetric Analysis (TGA)

The TGA analysis was performed by the Mettler-Toledo instrument (Mettler-Toledo, Columbus, OH, USA) over a temperature range of 25 °C to 400 °C with a heating rate of 10 °C/min. Alumina (aluminum oxide, ALU) crucibles were used to hold 1–2 mg of each sample.

3.6. Preparation of Encapsulation Complex

The complexes of CUR with different modified γ-CDs were performed via the solvent evaporation encapsulation technique. A 1:1 CUR to modified γ-CDs ratio (0.04 mmol, 16.00 mg) of CUR was dissolved in 1.0 mL methanol and 0.04 mmol of modified γ-CD (1.96, 2.00, and 2.00 mg for γ-CD-NHCH₂CH₂NH₂, γ-CD-NHCH₂CH₂OH, and γ-CD-NH₂, respectively), dissolved in 2.0 mL PBS buffer at pH 7.4. CUR solution was added dropwise into modified γ-CDs solutions then mixed by shaking at 40 °C for 24 h without evaporating the organic solvent completely. The uncomplexed drug was removed afterwards by centrifugation at 1500 rpm for 10 min [24,25].
3.7. Spectrophotometric Studies

The absorption spectrum, stoichiometry, and the formation constant of the inclusion complexes were determined by spectroscopic studies. The range of 300 to 500 nm using a Nanodrop 2000 UV–Vis spectrophotometer was utilized to obtain absorption spectra [26,27]. The continuous variation method (Job’s method) was employed to determine the complexation stoichiometry [23]. In this experiment, the samples were prepared by mixing various volumes of the two solutions (the same molar concentrations of the CUR and modified γ-CDs) to give the total concentration constant and the molar fraction of CUR, with X varying in the range from 0 to 1. The value of X gives the stoichiometry of inclusion complex (X = 0.5 for 1:1 ratio complex; X = 0.33 for 1:2 ratio complexes) [28]. The binding constant of the CUR-γ-CD inclusion complex was determined by the Benesi–Hildebrand equation [29]. The concentration of CUR was maintained at a constant (0.04 mM) throughout the experiment, whereas modified γ-CDs’ concentration varied from 1 to 3 molar ratios.

The binding constant \( (K_f) \) for the 1:1 ratio between modified γ-CDs and the CUR inclusion complex was determined using the Benesi–Hildebrand (Equation (1)), using a plot of \( 1/A - A_o \) versus \( 1/[\text{modified γ-CDs}] \)

\[
1/A - A_o = 1/A' - A_o + 1/K_f(A' - A_o)\gamma - CD
\]

where \( A_o \) is the absorbance of the guest without modified γ-CDs, \( A \) is the absorbance with a particular concentration of modified γ-CDs, and \( A' \) is the absorbance at the maximum concentration of modified γ-CDs.

The formation constant \( (K_f) \) can be calculated using Equation (2).

\[
K_f = \frac{1}{\text{slope} (A' - A_o)}
\]

3.8. Cells Culture

Certified pure unloaded cyclodextrin compounds, γ-CD, γ-CD-NHCH₂CH₂NH₂, γ-CD-NH₂, and γ-CD-NHCH₂CH₂OH, were tested for their in vitro cytotoxic activities. The human dermal fibroblast cell line (HDF) was cultured in Dulbecco’s modified Eagle medium (DMEM) (Euroclone SpA, Pero, Italy). DMEM was supplemented with 10% (\( v/v \)) fetal bovine serum (FBS), 100 U/mL of penicillin, 100 mg/mL of streptomycin, and 2 mM of L-Glutamine, and was maintained in an incubator (Memmert, Büchenbach, Germany) at 37 °C under an atmosphere of 5% CO₂ and 90% relative humidity. The cells were sub-cultivated approximately every 2 to 3 days using 0.05% (\( w/v \)) trypsin-EDTA.

3.9. Cell Viability Assay

HDF cells (5 \times 10^3 cells per well) were seeded in 96-well plates. After 24 h, the cells were treated with serial dilution of each of the γ-CD, γ-CD-NHCH₂CH₂NH₂, γ-CD-NH₂, and γ-CD-NHCH₂CH₂OH in the concentration range of 0.0 to 500 µM for 72 h. After 72 h of incubation at 37 °C, the treatment was removed from the wells, and was followed by adding 15 µL of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) solution and 100.00 µL of the medium. After 3 h of incubation, the medium was removed, and then 50.00 µL of dimethyl sulphoxide (DMSO) was added to dissolve the formazan. The absorbance was measured at a wavelength of 570 nm using a Glomax microplate reader (Promega, Madison, WI, USA) [30].

HDF cells were treated with serial concentrations of γ-CD, γ-CD-NH₂, γ-CD-NHCH₂CH₂OH, and γ-CD-NHCH₂CH₂NH₂ for 72 h. The cell’s viability was determined by the MTT assay. Data mean ± SD (\( n = 3 \)).
**Supplementary Materials:** The following supporting information can be downloaded at, Figure S1: 1H NMR spectrum of γ-CD; Figure S2: 13C-NMR spectrum of γ-CD in d6-DMSO; Figure S3: 13C-dept 135-NMR spectrum of γ-CD in d6-DMSO; Figure S4: 1H-15N-HMBC spectrum of γ-CD-NHCH2CH2NH2 (in 80% d6-DMSO/D2O at 25 °C); Figure S5: 1H-NMR spectrum of γ-CD-NHCH2CH2OH in D2O at 25 °C; Figure S6: 13C-NMR spectrum of γ-CD-NHCH2CH2OH in d6-DMSO at 25 °C.

**Author Contributions:** Conceptualization, supervision, investigation, and writing—review and editing, F.O., A.M.J. and W.A.; methodology, investigation, validation, data curation, formal analysis, and writing—original draft preparation, F.A. and H.N.; methodology and investigation, D.A.A.; supervision, validation, and writing—review and editing, A.A.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds in this study are not available from the authors.

**References**

1. Wupper, S.; Lüersen, K.; Rimbach, G. Cyclodextrins, Natural Compounds, and Plant Bioactives—A Nutritional Perspective. *Biomolecules* 2021, 11, 401. [CrossRef] [PubMed]

2. Crini, G. Review: A History of Cyclodextrins. *Chem. Rev.* 2014, 114, 10940–10975. [CrossRef] [PubMed]

3. Silva, A.F.; Monteiro, M.; Resende, D.; Braga, S.S.; Coimbra, M.A.; Silva, A.; Cardoso, S.M. Inclusion Complex of Resveratrol with γ-Cyclodextrin as a Functional Ingredient for Lemon Juices. *Foods* 2020, 10, 16. [CrossRef] [PubMed]

4. Schmidt, B.V.K.J.; Hetzer, M.; Ritter, H.; Barner-Kowollik, C. Complex macromolecular architecture design via cyclodextrin host/guest complexes. *Prog. Polym. Sci.* 2014, 39, 235–249. [CrossRef]

5. Kyba, E.P.; Helgeson, R.C.; Madan, K.; Gokel, G.W.; Tarnowski, T.L.; Moore, S.S.; Cram, D.J. Host-guest complexation. 1. Concept and illustration. *J. Am. Chem. Soc.* 1977, 99, 2564–2571. [CrossRef]

6. Liu, J.Y.; Zhang, X.; Tian, B.R. Selective modifications at the different positions of cyclodextrins: A review of strategies. *Turk. J. Chem.* 2020, 44, 261–278. [CrossRef]

7. Hsu, C.M.; Yu, S.C.; Tsai, F.J.; Tsai, Y. Characterization of in vitro and in vivo bioactivity of a ferulic acid-2-Hydroxypropyl-β-cyclodextrin inclusion complex. *Colloids Surf. B Biointerfaces* 2019, 180, 68–74. [CrossRef]

8. Mori, T.; Tsuchiya, R.; Doi, M.; Nagatani, N.; Tanaka, T. Solubilization of ultraviolet absorbers by cyclodextrin and their potential application in cosmetics. *J. Incl. Phenom. Macrocycl. Chem.* 2019, 93, 91–96. [CrossRef]

9. Molnár, Á. Synthetic Application of Cyclodextrins in Combination with Metal Ions, Complexes, and Metal Particles. *ChemCatChem* 2021, 13, 1424–1474. [CrossRef]

10. Saokham, P.; Loftsson, T. γ-Cyclodextrin. *Int. J. Pharm.* 2017, 516, 278–292. [CrossRef]

11. Yadav, V.R.; Prasad, S.; Kannappan, R.; Ravindran, J.; Chaturvedi, M.M.; Vaahthera, L.; Parkkinen, J.; Aggarwal, B.B. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and anti proliferative activities superior to those of curcumin through higher cellular uptake. *Biochem. Pharmacol.* 2010, 80, 1021–1032. [CrossRef] [PubMed]

12. Dandawate, P.R.; Vyas, A.; Ahmad, A.; Banerjee, S.; Deshpande, J.; Swamy, K.V.; Jamadar, A.; Dumbe-Klaire, A.C.; Padhye, S.; Sarkar, F.H. Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. *Pharm. Res. Res.* 2012, 29, 1775–1786. [CrossRef] [PubMed]

13. Zhang, L.; Man, S.; Qiu, H.; Liu, Z.; Zhang, M.; Ma, L.; Gao, W. Curcumin-cyclodextrin complexes enhanced the anti-cancer effects of curcumin. *Environ. Toxicol. Pharmacol.* 2016, 48, 31–38. [CrossRef] [PubMed]

14. Dong, L.; Liu, M.; Chen, A.; Wang, Y.; Sun, D. Solubilities of quercetin in three γ-cyclodextrin derivative solutions at different temperatures. *J. Mol. Liq.* 2013, 177, 204–208. [CrossRef]

15. Odeh, F.; Nsairat, H.; Alshaer, W.; Alsotari, S.; Buqain, R.; Ismail, S.; Awidi, A.; Al Bawab, A. Remote loading of curcumin-inmodified β-cyclodextrins into liposomes using a transmembrane pH gradient. *RSC Adv.* 2019, 9, 37148–37161. [CrossRef]

16. Albers, E.; Muller, B.W. Cyclodextrin derivatives in pharmaceutics. *Crit. Rev. Ther. Drug Carr. Syst.* 1995, 12, 311–337. [CrossRef]

17. Kellett, K.; Kantonen, S.A.; Duggan, B.; Gilson, M.K. Toward Expanded Diversity of Host-Guest Interactions via Synthesis and Characterization of Cyclodextrin Derivatives. *J. Solut. Chem.* 2018, 47, 1597–1608. [CrossRef]

18. Řezanka, P.; Navrátilová, K.; Řezanka, M.; Král, V.; Sýkora, D. Application of cyclodextrins in chiral capillary electrophoresis. *Electrophoresis* 2014, 35, 2701–2721. [CrossRef]
19. Liang, W.; Huang, Y.; Lu, D.; Ma, X.; Gong, T.; Cui, X.; Yu, B.; Yang, C.; Dong, C.; Shuang, S. β-Cyclodextrin-Hyaluronic Acid Polymer Functionalized Magnetic Graphene Oxide Nanocomposites for Targeted Photo-Chemotherapy of Tumor Cells. Polymers 2019, 11, 133. [CrossRef]

20. Nsairat, H.; Mahmoud, I.S.; Odeh, F.; Abuarqoub, D.; Al-Azzawi, H.; Zaza, R.; Qadri, M.I.; Ismail, S.; Al Bawab, A.; Awidi, A.; et al. Grafting of anti-nucleolin aptamer into preformed and remotely loaded liposomes through aptamer-cholesterol post-insertion. RSC Adv. 2020, 10, 36219-36229. [CrossRef]

21. Tang, W.; Ng, S.C. Facile synthesis of mono-6-amino-6-deoxy-α-,β-, γ-cyclodextrin hydrochlorides for molecular recognition, chiral separation and drug delivery. Nat. Protoc. 2008, 3, 691–697. [CrossRef] [PubMed]

22. Kohata, S.; Jyodoi, K.; Ohyoshi, A. Thermal decomposition of cyclodextrins (α, β., and γ modified α-CYD) and of metal - (α-CYD) complexes in the solid phase. Thermochim. Acta 1993, 217, 187–198. [CrossRef]

23. Rajaram, R.; Sundararajalu, K.N.; Meenakshisundaram, S. Unusual exited state characteristics of 6-aminobenzothiazole with β-cyclodextrin. J. Fluoresc. 2011, 21, 521–529. [CrossRef]

24. Hashimoto, S.; Thomas, J.K. Fluorescence study of pyrene and naphthalene in cyclodextrin-amphiphile complex system. J. Am. Chem. Soc. 1985, 107, 4655–4662. [CrossRef]

25. Sayed, M.; Gubbala, G.K.; Pal, H. Contrasting interactions of DNA-intercalating dye acridine orange with hydroxypropyl derivatives of β-cyclodextrin and γ-cyclodextrin hosts. New J. Chem. 2019, 43, 724–736. [CrossRef]

26. Saokham, P.; Muankaew, C.; Jansook, P.; Loftsson, T. Solubility of cyclodextrin and drug/cyclodextrin complexes. Molecules 2018, 23, 1161. [CrossRef]

27. Wang, H.Y.; Han, J.; Feng, X.G. Spectroscopic of orange γ-β-cyclodextrin complex and its analytical application. Spectrochim. Acta Mol. Biomol. Spectrosc. 2007, 66, 578–785. [CrossRef]

28. Srivivasan, K.; Stalin, T.; Sivakumar, K. Spectral, and electrochemical study of host-guest inclusion complex between 2,4-dinitrophenol and β-cyclodextrin. Spectrochim. Acta Mol. Biomol. Spectrosc. 2012, 94, 89–100. [CrossRef]

29. De Azevedo, M.; Alderete, J.B.; Lino, A.; Loh, W.; Faljoni-Alario, A.; DurAnn, N. Violacein/β-cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism. J. Incl. Phenom. Macrocycl. Chem. 2000, 37, 67–74. [CrossRef]

30. Lavorgna, M.; Iacovino, R.; Russo, C.; Di Donato, C.; Piscitelli, C.; Isidori, M. A new approach for improving the antibacterial and tumor cytotoxic activities of piperemic acid by including it in trimethyl—β-cyclodextrin. Int. J. Mol. Sci. 2019, 20, 416. [CrossRef]